Summary
Galectin-3, a β-galactoside-binding lectin, is a new important player in the progression of heart failure (HF) and is also linked to poor outcome in patients with cardiovascular disease. Genetic or pharmacological inhibition of galectin-3 slows down the progression of myocardial inflammation, reduces collagen production, attenuates cardiac remodelling, and ameliorates cardiac function. In this review, we summarize recent progress in research on galectin-3 as a regulatory molecule involved in cardiovascular fibrosis in HF and its potential role in the diagnosis, risk assessment and treatment of cardiovascular diseases.
K E Y W O R D S
aldosterone, angiotenin II, cardiovascular disease, fibrosis, galectin-3 Galectin-3 is widely distributed in the body, but the expression level varies among different organs. In addition, galectin-3 is highly expressed in many human tumours and cell lines, such as myeloid cells, 19 inflammatory cells (macrophages, mast cells, neutrophils, T cells, eosinophils, etc.), 20 fibroblasts 21 and cardiomyocytes. 8 
| B I OLOG I C AL ROLE S OF G ALEC TIN -3
Galectin-3 is a multifunctional protein that plays essential roles in many physiological and pathological processes, including cell growth, differentiation, apoptosis, cell adhesion, angiogenesis, inflammation, fibrogenesis and tumour progression. Studies have shown that galectin-3 prevents cytochrome c release and oxidative mitochondrial damage by regulating synexin expression. 25 In addition, galectin-3 participates in various inflammatory responses. Galectin-3 can act as an opsonin and initiate clearance by promoting macrophage efferocytosis. 27 Increased intracellular galectin-3 expression results in myofibroblast and macrophage 28 activation and tissue fibrosis.
Galectin-3 protein is also expressed in the nucleus. Nuclear galectin-3 has been reported to have a wide range of functions.
In the nucleus, galectin-3 associates with the components of the ribonucleoprotein complex. 29 Dagher et al 29 reported that galectin-3 acts as a precursor mRNA splicing factor and participates in spliceosome assembly. Moreover, Park et al 30 showed a galectin-3 interaction with pre-mRNA through protein complexes containing Gemin4. Galectin-3 also participates in regulating the Wnt/β-catenin signalling pathway in the nucleus. 31 Interestingly, galectin-3 protein abundance is significantly increased in the nucleus during cell proliferation of certain cell types, such as tumour cells and monocytes. 32 Gleissner et al 33 reported that galectin-3 interacts directly with the homology domain of thyroid-specific transcription factor 1 (TTF-1)
and stimulates the DNA-binding activity of TTF-1, thereby upregulating TTF-1 transcriptional activity and promoting thyroid cell proliferation. In addition, galectin-3 can regulate the expression of certain genes, including cancer-related genes such as cyclin D1 and mucin 2 34 ; however, the mechanisms underlying this regulatory activity is still unknown.
Lacking a conventional secretion signal sequence, galectin-3, similar to other galectin proteins, is secreted by a non-classical pathway that bypasses the reticulum-Golgi apparatus. 35 Extracellular or cell surface-bound galectin-3 binds to a variety of extracellular matrix (ECM) ligands, such as laminin, fibronectin, mucin, MAC-2 binding proteins, and macrophage surface antigens, thereby participating in cell-cell and cell-matrix adhesion. Binding to these proteins can be inhibited by lactose. 34 Ortega et al 36 reported that extracellular galectin-3 is an indispensable player in cartilage and bone-matrix remodelling of endochondral ossification. In contrast to its intracellular effects, galectin-3 induces apoptosis of T cells and monocytes and contributes to growth and differentiation of B and T cells. 16 A galectin-3-von Willebrand factor interaction modulates thrombus formation. 37 Furthermore, a galectin-3-hensin interaction promotes hensin oligomerization, which is considered to be essential for renal adaptation during metabolic acidosis. 38 Increased extracellular galectin-3 expression has been identified in some human diseases such as organ fibrosis, tumour development and progression, neural degeneration, atherosclerosis, diabetes, and HF.
16,39
| G ALEC TIN -3 IN C ARD IAC FIB ROS IS
The important role of galectin-3 in HF was first described by
Sharma et al 5 in a study indicating that galectin-3 was the strongest differentially regulated gene associated with HF. Subsequently, an elevated level of myocardial galectin-3 has been observed in a number of animal models of heart disease, such as hypertensive rats 5 prone to HF, interferon-γ-induced chronic active myocarditis and cardiomyopathy, 40 rat angiotensin II (AngII)-induced hypertension, 41 streptozotocin-induced diabetic cardiomyopathy 42 and pulmonary artery banding-induced HF in both left ventricle (LV) and right ventricle (RV). 8 Mainly expressed in activated macrophages and pathologically damaged cardiomyocytes, galectin-3 is considered an active contributor to cardiac remodelling, including myocardial fibrogenesis, and to the development of HF. 7, 43, 44 Galectin-3 induces fibroblast proliferation and heterogeneous deposition of collagen types, eventually leading to loss of cardiac function. 5, 8 Injection of galectin-3 in the pericardial cavity of rats significantly increased the degree of myocardial fibrosis and ventricular remodelling. This damage was accompanied by reductions in LV ejection fraction and cardiac output. 5 Genetic and pharmacological inhibition of galectin-3 interferes with myocardial fibrogenesis, prevents cardiac remodelling, and significantly reduces the formation of myocardial fibrosis. 
| REG UL ATORY MECHANIS M OF G ALEC TIN -3 IN C ARD IAC FIB ROS IS
The possible mechanisms by which galectin-3 mediates cardiac fi- tion. 45 We demonstrated that increasing galectin-3 protein expression by the galectin-3 gene promotes collagen I synthesis in HL-I cardiomyocytes, which promotes cardiac decompensation. 8 Interestingly, new studies published in 2018 by Ibarrola et al 46, 47 revealed that galectin-3 can promote oxidative stress in human cardiac fibroblasts and in animal and human models of cardiac diseases, a novel mechanism of galectin-3-induced cardiac damage. Oxidative stress is a disturbance in the balance between reactive oxygen species (ROS) production and antioxidant detoxification. In patients with HF, oxidative stress occurs in the myocardium 48 and correlates with left ventricular dysfunction. 49 Galectin-3 downregulated the protective fumarate hydratase, increased fumarate production and promoted oxidative stress-related mediator release. 46 Moreover, galectin-3 increased peroxide, nitrotyrosine, malondialdehyde, and N-carboxymethyl-lysine levels and decreased total antioxidant capacity. 47 In addition, galectin-3 was also reported to increase the expression of Nox4 in cardiac cells and regulate Nox4-derived ROS levels during cardiac fibrosis. 50 Therefore, reducing oxidative stress and improving antioxidant defences by inhibiting galectin-3 could be a promising approach to reduce cardiac damage in HF.
| G ALEC TIN -3 IN ALDOS TERONE-INDUCED HE ART FIB ROTIC RE S P ON S E
Aldosteronism is considered the most common cause of secondary hypertension. Patients with primary aldosteronism have a high risk of myocardial fibrosis and myocardial inflammation. 51 Since aldosterone is a key factor in the process of fibrosis, the use of fibrosis. In a prospective clinical follow-up study, serum galectin-3 levels were significantly higher in patients with an aldosteroneproducing adenoma. The level of serum galectin-3 and the degree of myocardial fibrosis after adrenalectomy were significantly decreased. 55 In an animal study, two groups of rats were treated with different drugs, and the control group was given aldosterone/salt for 3 weeks. The experimental groups were given MRA spironolactone or the galectin-3 inhibitor, modified citrus pectin (MCP), for 3 weeks. Rats in the control group had hypertension, inflammation, fibrosis, vascular hypertrophy, and increased expression of galectin-3 in the aorta. In contrast, the test group treated with spironolactone or MCP, that had also received aldosterone and salt stimulation, showed a marked decrease in myocardial fibrosis and inflammation. 57 In an animal model of myocardial infarction induced by permanent ligation of the left anterior descending coronary artery, 58 the expression of galectin-3, TGF-β and SMAD-3 was significantly decreased 4 weeks after myocardial infarction in rats treated with spironolactone or eplerenone. 59 The role of galectin-3 in aldosterone-induced pro-inflammatory and pro-fibrotic responses was investigated in galectin-3 knockout (KO) mice. Wild-type (WT) and galectin-3 KO mice were treated with aldosterone for 3 or 6 weeks, and the levels of inflammation, type I collagen and galectin-3 in the aorta of WT mice were enhanced by aldosterone stimulation regardless of the time of aldosterone treatment. However, no changes were observed in the KO mice.
60
In vitro studies with rat vascular smooth muscle cells (VSMC) 60 and human cardiac fibroblasts 61 
| G ALEC TIN -3 IN ANG II -PKC-INDUCED C ARD IAC FIB ROS IS
Activation of protein kinase C (PKC) is associated with cardiac hypertrophy and HF. [62] [63] [64] [65] [66] Furthermore, PKC expression is the highest in fetal and neonatal hearts and gradually decreases with age. Multiple PKC isoforms have been identified in the heart. PKC-α is one of the most highly expressed PKCs in cardiomyocytes. 66 In the end phase of HF, PKC-α was shown to be upregulated, and its activity was increased. 65 A reduction in PKC-α levels by siRNA knockdown alleviated pressure overload-induced cardiac hypertrophy and HF. [65] [66] [67] Since both PKC and galectin-3 are increased in HF and linked to cardiac hypertrophy and myocardial, 5, 65 we explored the possi- 
| G ALEC TIN -3 IN DOX A ZOS IN -INDUCED C ARD IAC INJ URY
Doxazosin, a selective long-acting inhibitor of α-adrenergic receptors, is commonly used to treat hypertension 70, 71 and benign prostatic hyperplasia. 72, 73 However, studies have shown that doxazosin can increase the risk of heart disease, especially congestive HF. 74 A recent study showed that doxazosin treatment increased galectin-3 expression and collagen synthesis in HL-1 cardiomyocytes. 9 These findings indicate that the mechanism by which doxazosin causes heart damage and HF is at least partially mediated by increasing galectin-3 expression. However, pretreatment of cells with PKC inhibitors or adrenergic receptor blockers did not inhibit doxazosin-induced galectin-3 and collagen expression, suggesting that molecular pathways other than PKC and adrenergic receptors are involved in doxazosin-stimulated galectin-3 expression and myocardial damage.
| G ALEC TIN -3 IN HF RIS K A SS E SS MENT AND D IAG NOS IS
Clinically, the serum galectin-3 levels in patients with HF are significantly increased, 43, 44, 75 and the continuously increasing galectin-3 levels are often associated with a greater risk of adverse cardiovascular events, 76, 77 providing that galectin-3 most likely serves as a predictive biomarker for the severity of cardiac fibrosis and HF. In a large, community-based cohort study involving more than 8000 participants, de Boer et al 78 showed that elevated levels of galectin-3 are closely linked to cardiovascular disease and all-cause mortality.
Furthermore, in a cohort study of 44 ischaemic cardiomyopathy and 36 dilated cardiomyopathy patients, patients with dilated cardiomyopathy had significantly elevated levels of galectin-3. 79 In another study, galectin-3 levels predicted myocardial fibrosis replacement in nonischaemic dilated cardiomyopathy patients. 80 Due to its significant role in mediating cardiac disease, galectin-3 was approved by the Food and Drug Administration in 2010 as a novel biomarker for predicting cardiovascular adverse events and for use in conjunction with clinical evaluation.
| CON CLUS ION
Accumulating studies demonstrate that galectin-3 is upregulated in clinical and experimental HF and plays an important role in the pathogenesis of cardiac fibrosis. Inhibition of galectin-3 activation after heart injury may provide an alternative therapeutic approach in the prevention and treatment of HF.
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